Abstract
Cancer is one of the most frequent causes of global mortality with about ten million deaths reported in 2020, according to the World Health Organization (WHO). The present-day cancer armamentarium typically possesses limitations viz. lack of specificity, high toxicity, multidrug resistance, and other threatening side effects. Thus, there remains a need for novel antitumor drugs with high efficacy and minimum side effects. The use of live oncolytic bacteria has emerged as a plausible approach to meet these challenges. These tumor-targeted bacteria can proliferate in the cancer cells, initiate the immune response, and suppress the cancers. In addition, microbes also produce a variety of peptides, enzymes, toxins, other proteins, and several secondary metabolites, which have emerged as promising candidates for cancer therapy. The present chapter elaborates upon the various attributes of these bio-drugs such as sources, mode of action, targeted cancers, toxicity issues, and clinical status. In addition, the recent approaches to improve the efficacy and safety of therapeutic bacteria and their products are briefly discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
AlQahtani AD, Al-Mansoori L, Bashraheel SS, Rashidi FB, Al-Yafei A, Elsinga P, Domling A, Goda SK (2019) Production of “biobetter” glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment. Eur J Pharm Sci 127:79–91. https://doi.org/10.1016/j.ejps.2018.10.014
Avramis VI, Tiwari PN (2006) Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine 1(3):241–254
Azevedo MM, Pina-Vaz C, Baltazar F (2020) Microbes and cancer: friends or faux? Int J Mol Sci 21(9):3115. https://doi.org/10.3390/ijms21093115
Bailly J, Sezanne V, Godfrin Y (2011) L-asparaginase loaded red blood cells: from prescription to injection. Blood 118(21):4252. https://doi.org/10.1182/blood.V118.21.4252.4252
Baindara P, Gautam A, Raghava GPS, Korpole S (2017) Anticancer properties of a defensin like class IId bacteriocin Laterosporulin 10. Sci Rep 7:46541. https://doi.org/10.1038/srep46541
Bantel H, Sinha B, Domschke W, Peters G, Schulze-Osthoff K, Jänicke RU (2001) α-Toxin is a mediator of Staphylococcus aureus–induced cell death and activates caspases via the intrinsic death pathway independently of death receptor signaling. J Cell Biol 155(4):637–648. https://doi.org/10.1083/jcb.200105081
Basu P, Mehta A, Jain M, Gupta S, Nagarkar RV, John S, Petit R (2018) A randomized phase 2 study of ADXS11-001 listeria monocytogenes-Listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer. Int J Gynecol Cancer 28(4):764–772. https://doi.org/10.1097/IGC.0000000000001235
Binz N, Shalaby T, Rivera P, Shin-ya K, Grotzer MA (2005) Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells. Eur J Cancer 41(18):2873–2881. https://doi.org/10.1016/j.ejca.2005.08.025
Blackman LD, Varlas S, Arno MC, Houston ZH, Fletcher NL, Thurecht KJ, Hasan M, Gibson MI, O’Reilly RK (2018) Confinement of therapeutic enzymes in selectively permeable polymer vesicles by polymerization-induced self-assembly (Pisa) reduces antibody binding and proteolytic susceptibility. ACS Cent Sci 4(6):718–723. https://doi.org/10.1021/acscentsci.8b00168
Braun V, Pilsl H, Groß P (1994) Colicins: structures, modes of action, transfer through membranes, and evolution. Arch Microbiol 161(3):199–206. https://doi.org/10.1007/BF00248693
Brumano LP, da Silva FVS, Costa-Silva TA, Apolinário AC, Santos JHPM, Kleingesinds EK, Monteiro G, Rangel-Yagui C et al (2019) Development of L-Asparaginase biobetters: current research status and review of the desirable quality profiles. Front Bioeng Biotechnol 6:212. https://doi.org/10.3389/fbioe.2018.00212
Cavuoto P, Fenech MF (2012) A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension. Cancer Treat Rev 38(6):726–736. https://doi.org/10.1016/j.ctrv.2012.01.004
Cellarier E, Durando X, Vasson MP, Farges MC, Demiden A, Maurizis JC, Madelmont JC, Chollet P (2003) Methionine dependency and cancer treatment. Cancer Treat Rev 29(6):489–499. https://doi.org/10.1016/S0305-7372(03)00118-X
Chang W-W, Lai C-H, Chen M-C, Liu C-F, Kuan Y-D, Lin S-T, Lee C-H (2013) Salmonella enhance chemosensitivity in tumor through connexin 43 upregulation. Int J Cancer 133(8):1926–1935. https://doi.org/10.1002/ijc.28155
Chumchalová J, Šmarda J (2003) Human tumor cells are selectively inhibited by colicins. Folia Microbiol 48(1):111–115. https://doi.org/10.1007/BF02931286
Clairmont C, Lee KC, Pike J, Ittensohn M, Low KB, Pawelek J, Bermudes D, Brecher SM, Margitich D, Turnier J, Li Z, Luo X, King I, Zheng LM (2000) Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of salmonella typhimurium. J Infect Dis 181(6):1996–2002. https://doi.org/10.1086/315497
Coley WB (1991) The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 262:3–11
Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV (2009) Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules (Basel, Switzerland) 14(11):4517–4545. https://doi.org/10.3390/molecules14114517
Dang LH, Bettegowda C, Agrawal N, Cheong I, Huso D, Frost P, Loganzo F, Greenberger L, Barkoczy J, Pettit GR, Smith AB, Gurulingappa H, Khan S, Parmigiani G, Kinzler KW, Zhou S, Vogelstein B (2004) Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. Cancer Biol Ther 3(3):326–337. https://doi.org/10.4161/cbt.3.3.704
Dhankhar R, Gulati P, Kumar S, Kapoor RK (2018) Arginine-lowering enzymes against cancer: a technocommercial analysis through patent landscape. Expert Opin Ther Pat 28(8):603–614. https://doi.org/10.1080/13543776.2018.1508452
Dhankhar R, Gupta V, Kumar S, Kapoor RK, Gulati P (2020) Microbial enzymes for deprivation of amino acid metabolism in malignant cells: biological strategy for cancer treatment. Appl Microbiol Biotechnol 104(7):2857–2869. https://doi.org/10.1007/s00253-020-10432-2
Dhankhar R, Kawatra A, Mohanty A, Gulati P (2021) Microbial enzymes used in prodrug activation for cancer therapy: insights and future perspectives. Curr Protein Pept Sci 22(7):514–525. https://doi.org/10.2174/1389203721666201207231932
Dhankhar R, Kumar A, Kumar S, Chhabra D, Shukla P, Gulati P (2019) Multilevel algorithms and evolutionary hybrid tools for enhanced production of arginine deiminase from pseudomonas furukawaii RS3. Bioresour Technol 290:121789. https://doi.org/10.1016/j.biortech.2019.121789
Dincer S, Takci HAM, Ozdenefe MS, Dincer S, Takci HAM, Ozdenefe MS (2022) Nonribosomal peptide synthesis. In: Molecular cloning. IntechOpen, London. https://doi.org/10.5772/intechopen.104722
Ding H, Liu H, Yin Y, Ding Y, Jia Y, Chen Q, Zou G, Zheng Z (2012) Insights into the modulation of optimum pH by a single histidine residue in arginine deiminase from Pseudomonas aeruginosa. Biol Chem 393(9):1013–1024. https://doi.org/10.1515/hsz-2012-0183
do Vale A, Cabanes D, Sousa S (2016) Bacterial toxins as pathogen weapons against phagocytes. Front Microbiol 7:42. https://doi.org/10.3389/fmicb.2016.00042
Duong MT-Q, Qin Y, You S-H, Min J-J (2019) Bacteria-cancer interactions: Bacteria-based cancer therapy. Exp Mol Med 51(12):1–15. https://doi.org/10.1038/s12276-019-0297-0
El-Sayed AS (2010) Microbial L-methioninase: production, molecular characterization, and therapeutic applications. Appl Microbiol Biotechnol 86(2):445–467. https://doi.org/10.1007/s00253-009-2303-2
Engedal N, Skotland T, Torgersen ML, Sandvig K (2011) Shiga toxin and its use in targeted cancer therapy and imaging. Microb Biotechnol 4(1):32–46. https://doi.org/10.1111/j.1751-7915.2010.00180.x
Falzone L, Salomone S, Libra M (2018) Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol 9:1300. https://doi.org/10.3389/fphar.2018.01300
Fernandes HS, Silva Teixeira CS, Fernandes PA, Ramos MJ, Cerqueira NMFSA (2017) Amino acid deprivation using enzymes as a targeted therapy for cancer and viral infections. Expert Opin Ther Pat 27(3):283–297. https://doi.org/10.1080/13543776.2017.1254194
Fiedler H-P, Bruntner C, Riedlinger J, Bull AT, Knutsen G, Goodfellow M, Jones A, Maldonado L, Pathom-aree W, Beil W, Schneider K, Keller S, Sussmuth RD (2008) Proximicin A, B and C, novel aminofuran antibiotic and anticancer compounds isolated from marine strains of the actinomycete Verrucosispora. J Antibiot 61(3):158–163. https://doi.org/10.1038/ja.2008.125
Gallego J, Ortiz AR, de Pascual-Teresa B, Gago F (1997) Structure–affinity relationships for the binding of actinomycin D to DNA. J Comput Aided Mol Des 11(2):114–128. https://doi.org/10.1023/A:1008018106064
Ganai S, Arenas RB, Sauer JP, Bentley B, Forbes NS (2011) In tumors salmonella migrate away from vasculature toward the transition zone and induce apoptosis. Cancer Gene Ther 18(7):457–466. https://doi.org/10.1038/cgt.2011.10
Gardlík R, Pálffy R, Hodosy J, Lukács J, Turna J, Celec P (2005) Vectors and delivery systems in gene therapy. Med Sci Monit 11(4):RA110-121
Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, Thaiss CA, Reuben A, Livny J, Avraham R, Frederick DT, Ligorio M, Chatman K, Johnston SE, Mosher CM, Straussman R (2017) Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357(6356):1156–1160. https://doi.org/10.1126/science.aah5043
Geyer PE, Maak M, Nitsche U, Perl M, Novotny A, Slotta-Huspenina J, Dransart E, Holtorf A, Johannes L, Janssen K-P (2016) Gastric adenocarcinomas express the glycosphingolipid Gb3/CD77: targeting of gastric cancer cells with Shiga toxin b-subunit. Mol Cancer Ther 15(5):1008–1017. https://doi.org/10.1158/1535-7163.MCT-15-0633
Goldufsky J, Wood S, Hajihossainlou B, Rehman T, Majdobeh O, Kaufman HL, Ruby CE, Shafikhani SH (2015) Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines. J Med Microbiol 64(Pt 2):164–173. https://doi.org/10.1099/jmm.0.000003-0
Greco O, Dachs GU (2001) Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 187(1):22–36. https://doi.org/10.1002/1097-4652(2001)9999:9999<::AID-JCP1060>3.0.CO;2-H
Gulati P, Kawatra A, Dhillon S, Dhankhar R (2022) Bacterial drug delivery vehicles for targeted treatment of tumors. In: Microbial products. CRC, Boca Raton, FL
Gupta KH, Nowicki C, Giurini EF, Marzo AL, Zloza A (2021) Bacterial-based cancer therapy (BBCT): recent advances, current challenges, and future prospects for cancer immunotherapy. Vaccine 9(12):1497. https://doi.org/10.3390/vaccines9121497
Hamamichi S, Fukuhara T, Hattori N (2020) Immunotoxin screening system: a rapid and direct approach to obtain functional antibodies with internalization capacities. Toxins 12:658. https://doi.org/10.3390/toxins12100658
Hens JR, Sinha I, Perodin F, Cooper T, Sinha R, Plummer J, Perrone CE, Orentreich D (2016) Methionine-restricted diet inhibits growth of MCF10AT1-derived mammary tumors by increasing cell cycle inhibitors in athymic nude mice. BMC Cancer 16(1):349. https://doi.org/10.1186/s12885-016-2367-1
Hetz C, Bono MR, Barros LF, Lagos R (2002) Microcin E492, a channel-forming bacteriocin from Klebsiella pneumoniae, induces apoptosis in some human cell lines. Proc Natl Acad Sci U S A 99(5):2696–2701. https://doi.org/10.1073/pnas.052709699
Hoffman RM, Tan Y, Li S, Han Q, Zavala J, Zavala J (2019) Pilot phase I clinical trial of methioninase on high-stage cancer patients: rapid depletion of circulating methionine. In: Hoffman RM (ed) Methionine dependence of cancer and aging: methods and protocols. Springer, Cham, pp 231–242. https://doi.org/10.1007/978-1-4939-8796-2_17
Holtsberg FW, Ensor CM, Steiner MR, Bomalaski JS, Clark MA (2002) Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release 80(1–3):259–271. https://doi.org/10.1016/s0168-3659(02)00042-1
Hoskin DW, Ramamoorthy A (2008) Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta Biomembr 1778(2):357–375. https://doi.org/10.1016/j.bbamem.2007.11.008
Iacovache I, Bischofberger M, van der Goot FG (2010) Structure and assembly of pore-forming proteins. Curr Opin Struct Biol 20(2):241–246. https://doi.org/10.1016/j.sbi.2010.01.013
Imre G, Heering J, Takeda A-N, Husmann M, Thiede B, Zu Heringdorf DM, Green DR, van der Goot FG, Sinha B, Dötsch V, Rajalingam K (2012) Caspase-2 is an initiator caspase responsible for pore-forming toxin-mediated apoptosis. EMBO J 31(11):2615–2628. https://doi.org/10.1038/emboj.2012.93
Jen EY, Gao X, Li L, Zhuang L, Simpson NE, Aryal B, Wang R, Przepiorka D, Shen YL, Leong R, Liu C, Sheth CM, Bowen S, Goldberg KB, Farrell AT, Blumenthal GM, Pazdur R (2020) FDA approval summary: Tagraxofusp-erzs for treatment of blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res 26(3):532–536. https://doi.org/10.1158/1078-0432.CCR-19-2329
Jiang S-N, Phan TX, Nam T-K, Nguyen VH, Kim H-S, Bom H-S, Choy HE, Hong Y, Min J-J (2010) Inhibition of tumor growth and metastasis by a combination of Escherichia coli–mediated cytolytic therapy and radiotherapy. Mol Ther 18(3):635–642. https://doi.org/10.1038/mt.2009.295
Jianhua C, Yujun W, Ruibo J, Min W, Wutong W (2006) Probing the antigenicity of E. coli L-asparaginase by mutational analysis. Mol Biotechnol 33(1):57–65. https://doi.org/10.1385/MB:33:1:57
Kaliberov SA, Market JM, Gillespie GY, Krendelchtchikova V, Della Manna D, Sellers JC, Kaliberova LN, Black ME, Buchsbaum DJ (2007) Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma. Gene Ther 14(14):1111–1119. https://doi.org/10.1038/sj.gt.3302965
Kannan S, Marudhamuthu M (2019) Development of chitin cross-linked enzyme aggregates of L-methioninase for upgraded activity, permanence and application as efficient therapeutic formulations. Int J Biol Macromol 141:218–231. https://doi.org/10.1016/j.ijbiomac.2019.08.246
Karpiński TM, Adamczak A (2018) Anticancer activity of bacterial proteins and peptides. Pharmaceutics 10(2):54. https://doi.org/10.3390/pharmaceutics10020054
Karpiński TM, Szkaradkiewicz AK (2013) Anti-cancer peptides from bacteria. Bangladesh J Pharmacol 8(3):Article 3
Kaur S, Kaur S (2015) Bacteriocins as potential anticancer agents. Front Pharmacol 6:272. https://doi.org/10.3389/fphar.2015.00272
Kawatra A, Dhankhar R, Gulati P (2022) Microbial arginine deiminase: a multifaceted green catalyst in biomedical sciences. Int J Biol Macromol 196:151–162. https://doi.org/10.1016/j.ijbiomac.2021.12.015
Kawatra A, Dhankhar R, Mohanty A, Gulati P (2020) Biomedical applications of microbial phenylalanine ammonia lyase: current status and future prospects. Biochimie 177:142–152. https://doi.org/10.1016/j.biochi.2020.08.009
Khoshnood S, Fathizadeh H, Neamati F, Negahdari B, Baindara P, Abdullah MA, Haddadi MH (2022) Bacteria-derived chimeric toxins as potential anticancer agents. Front Oncol 12:953678. https://doi.org/10.3389/fonc.2022.953678
Kim SH, Castro F, Paterson Y, Gravekamp C (2009) High efficacy of a listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res 69(14):5860–5866. https://doi.org/10.1158/0008-5472.CAN-08-4855
Kim M-Y, Vankayalapati H, Shin-ya K, Wierzba K, Hurley LH (2002) Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex. J Am Chem Soc 124(10):2098–2099. https://doi.org/10.1021/ja017308q
Knott SRV, Wagenblast E, Khan S, Kim SY, Soto M, Wagner M, Turgeon M-O, Fish L, Erard N, Gable AL, Maceli AR, Dickopf S, Papachristou EK, D’Santos CS, Carey LA, Wilkinson JE, Harrell JC, Perou CM, Goodarzi H, Hannon GJ (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554(7692):Article 7692. https://doi.org/10.1038/nature25465
Kostova V, Dransart E, Azoulay M, Brulle L, Bai S-K, Florent J-C, Johannes L, Schmidt F (2015) Targeted Shiga toxin–drug conjugates prepared via cu-free click chemistry. Bioorg Med Chem 23(22):7150–7157. https://doi.org/10.1016/j.bmc.2015.10.010
Kotzia GA, Labrou NE (2009) Engineering thermal stability of L-asparaginase by in vitro directed evolution. FEBS J 276(6):1750–1761. https://doi.org/10.1111/j.1742-4658.2009.06910.x
Law JW-F, Law LN-S, Letchumanan V, Tan LT-H, Wong SH, Chan K-G, Ab Mutalib N-S, Lee L-H (2020) Anticancer drug discovery from microbial sources: the unique mangrove Streptomycetes. Molecules 25(22):E5365. https://doi.org/10.3390/molecules25225365
Law D, Zhang Z (2007) Stabilization and target delivery of nattokinase using compression coating. Drug Dev Ind Pharm 33(5):495–503. https://doi.org/10.1080/03639040601050247
Lee DG, Hahm K-S, Park Y, Kim H-Y, Lee W, Lim S-C, Seo Y-K, Choi C-H (2005) Functional and structural characteristics of anticancer peptide pep 27 analogues. Cancer Cell Int 5(1):21. https://doi.org/10.1186/1475-2867-5-21
Liang X, Ji Y (2006) Alpha-toxin interferes with integrin-mediated adhesion and internalization of Staphylococcus aureus by epithelial cells. Cell Microbiol 8(10):1656–1668. https://doi.org/10.1111/j.1462-5822.2006.00740.x
Liang X, Ji Y (2007) Involvement of α5β1-integrin and TNF-α in Staphylococcus aureus α-toxin-induced death of epithelial cells. Cell Microbiol 9(7):1809–1821. https://doi.org/10.1111/j.1462-5822.2007.00917.x
Liu X, Gu K, Xia S-S, Zhang D-J, Li Y-G (2018) Dolyemycins A and B, two novel cyclopeptides isolated from Streptomyces griseus subsp. griseus HYS31. J Antibiot 71(10):838. https://doi.org/10.1038/s41429-018-0071-x
Llop-Hernández À, Verdura S, Cuyàs E, Menendez JA (2022) Nutritional niches of cancer therapy-induced senescent cells. Nutrients 14(17):Article 17. https://doi.org/10.3390/nu14173636
Lombó F, Velasco A, Castro A, de la Calle F, Braña AF, Sánchez-Puelles JM, Méndez C, Salas JA (2006) Deciphering the biosynthesis pathway of the antitumor thiocoraline from a marine actinomycete and its expression in two Streptomyces species. ChemBioChem 7(2):366–376. https://doi.org/10.1002/cbic.200500325
Luo X, Li Z, Lin S, Le T, Ittensohn M, Bermudes D, Runyab JD, Shen SY, Chen J, King IC, Zheng LM (2001) Antitumor effect of VNP20009, an attenuated salmonella, in murine tumor models. Oncol Res 12(11–12):501–508. https://doi.org/10.3727/096504001108747512
Maak M, Nitsche U, Keller L, Wolf P, Sarr M, Thiebaud M, Rosenberg R, Langer R, Kleeff J, Friess H, Johannes L, Janssen K-P (2011) Tumor-specific targeting of pancreatic cancer with Shiga toxin b-subunit. Mol Cancer Ther 10(10):1918–1928. https://doi.org/10.1158/1535-7163.MCT-11-0006
Maggi M, Mittelman SD, Parmentier JH, Colombo G, Meli M, Whitmire JM, Merrell DS, Whitelegge J, Scotti C (2017) A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro. Sci Rep 7(1):Article 1. https://doi.org/10.1038/s41598-017-15075-4
Mahboobi M, Sedighian H, Ch MH, Bambai B, Soofian SE, Amani J (2017) Applying bioinformatic tools for modeling and modifying type II E. coli L-asparginase to present a better therapeutic agent/drug for acute lymphoblastic leukemia. Int J Cancer Manag 10(3):Article 3. https://doi.org/10.5812/ijcm.5785
Malekshah OM, Chen X, Nomani A, Sarkar S, Hatefi A (2016) Enzyme/prodrug systems for cancer gene therapy. Curr Pharmacol Rep 2(6):299–308. https://doi.org/10.1007/s40495-016-0073-y
Mantovani HC, Hu H, Worobo RW, Russell JB (2002) Bovicin HC5, a bacteriocin from Streptococcus bovis HC5. Microbiology 148(Pt 11):3347–3352. https://doi.org/10.1099/00221287-148-11-3347
Matsuo H, Mochizuki H, Davies J, Sugiyama M (1997) Production of bleomycin N-acetyltransferase in Escherichia coli and Streptomyces verticillus. FEMS Microbiol Lett 153(1):83–88. https://doi.org/10.1111/j.1574-6968.1997.tb10467.x
Mayakrishnan V, Kannappan P, Tharmalingam N, Bose RJC, Madheswaran T, Ramasamy M (2022) Bacterial cancer therapy: a turning point for new paradigms. Drug Discov Today 27(8):2043–2050. https://doi.org/10.1016/j.drudis.2022.03.007
Melton-Celsa AR (2014) Shiga toxin (Stx) classification, structure, and function. Microbiol Spectr 2(2):EHEC-0024-2013. https://doi.org/10.1128/microbiolspec.EHEC-0024-2013
Meneguetti GP, Santos JHPM, Obreque KMT, Barbosa CMV, Monteiro G, Farsky SHP, Marim de Oliveira A, Angeli CB, Palmisano G, Ventura SPM, Pessoa-Junior A, de Oliveira Rangel-Yagui C (2019) Novel site-specific PEGylated L-asparaginase. PLoS One 14(2):e0211951. https://doi.org/10.1371/journal.pone.0211951
Mohan CD, Rangappa S, Nayak SC, Jadimurthy R, Wang L, Sethi G, Garg M, Rangappa KS (2021) Bacteria as a treasure house of secondary metabolites with anticancer potential. Semin Cancer Biol 86:998. https://doi.org/10.1016/j.semcancer.2021.05.006
Mooney R, Abdul Majid A, Batalla J, Annala AJ, Aboody KS (2017) Cell-mediated enzyme prodrug cancer therapies. Adv Drug Deliv Rev 118:35–51. https://doi.org/10.1016/j.addr.2017.09.003
Murphy JR (1996) Corynebacterium diphtheriae. In: Baron S (ed) Medical microbiology, 4th edn. University of Texas Medical Branch, Galveston. http://www.ncbi.nlm.nih.gov/books/NBK7971/
Nallar SC, Xu D-Q, Kalvakolanu DV (2017) Bacteria and genetically modified bacteria as cancer therapeutics: current advances and challenges. Cytokine 89:160–172. https://doi.org/10.1016/j.cyto.2016.01.002
Narsing Rao MP, Xiao M, Li W-J (2017) Fungal and bacterial pigments: secondary metabolites with wide applications. Front Microbiol 8:1113. https://doi.org/10.3389/fmicb.2017.01113
Nguyen HA, Su Y, Zhang JY, Antanasijevic A, Caffrey M, Schalk AM, Liu L, Rondelli D, Oh A, Mahmud DL, Bosland MC, Kajdacsy-Balla A, Peirs S, Lammens T, Mondelaers V, De Moerloose B, Goossens S, Schlicht MJ, Kabirov KK, Lavie A (2018) A novel l-asparaginase with low L-glutaminase coactivity is highly efficacious against both T- and B-cell acute lymphoblastic leukemias in vivo. Cancer Res 78(6):1549–1560. https://doi.org/10.1158/0008-5472.CAN-17-2106
Noei A, Nili-Ahmadabadi A, Soleimani M (2019) The enhanced cytotoxic effects of the p 28-apoptin chimeric protein as a novel anti-cancer agent on breast cancer cell lines. Drug Res 69(3):144–150. https://doi.org/10.1055/a-0654-4952
Oh S, Todhunter DA, Panoskaltsis-Mortari A, Buchsbaum DJ, Toma S, Vallera DA (2012) A deimmunized bispecific ligand-directed toxin that shows an impressive anti–pancreatic cancer effect in a systemic nude mouse orthotopic model. Pancreas 41(5):789–796. https://doi.org/10.1097/MPA.0b013e31823b5f2e
Oloomi M, Imani M, Behzadi R, Asori M, Bouzari S, Mokhlesi B (2018) Anti-tumor activity of Escherichia coli Shiga toxin a subunit delivered by SF9 insect cells. J Pharmacol Sci 138(1):71–75. https://doi.org/10.1016/j.jphs.2018.09.003
Ozdemir T, Fedorec AJH, Danino T, Barnes CP (2018) Synthetic biology and engineered live biotherapeutics: toward increasing system complexity. Cell Syst 7(1):5–16. https://doi.org/10.1016/j.cels.2018.06.008
Paiva AD, de Oliveira MD, de Paula SO, Baracat-Pereira MC, Breukink E, Mantovani HC (2012) Toxicity of bovicin HC5 against mammalian cell lines and the role of cholesterol in bacteriocin activity. Microbiology 158(Pt 11):2851–2858. https://doi.org/10.1099/mic.0.062190-0
Pinatih KJP, Suardana IW, Widiasih DA, Suharsono H (2021) Shiga-like toxin produced by local isolates of Escherichia coli O157:H7 induces apoptosis of the t47 breast cancer cell line. Breast Cancer 15:11782234211010120. https://doi.org/10.1177/11782234211010120
Raboni S, Revtovich S, Demitri N, Giabbai B, Storici P, Cocconcelli C, Faggiano S, Rosini E, Pollegioni L, Galati S, Buschini A, Morozova E, Kulikova V, Nikulin A, Gabellieri E, Cioni P, Demidkina T, Mozzarelli A (2018) Engineering methionine γ-lyase from Citrobacter freundii for anticancer activity. BBA-Proteins Proteom 1866(12):1260–1270. https://doi.org/10.1016/j.bbapap.2018.09.011
Rezai T, Yu B, Millhauser GL, Jacobson MP, Lokey RS (2006) Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. J Am Chem Soc 128(8):2510–2511. https://doi.org/10.1021/ja0563455
Riedl S, Rinner B, Asslaber M, Schaider H, Walzer S, Novak A, Lohner K, Zweytick D (2011) In search of a novel target—phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochim Biophys Acta Biomembr 1808(11):2638–2645. https://doi.org/10.1016/j.bbamem.2011.07.026
Risberg K, Fodstad Ø, Andersson Y (2011) Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma. PLoS One 6(9):e24012. https://doi.org/10.1371/journal.pone.0024012
Robert A, Wiels J (2021) Shiga toxins as antitumor tools. Toxins 13(10):690. https://doi.org/10.3390/toxins13100690
Schweizer F (2009) Cationic amphiphilic peptides with cancer-selective toxicity. Eur J Pharmacol 625(1):190–194. https://doi.org/10.1016/j.ejphar.2009.08.043
Sedighi M, Zahedi Bialvaei A, Hamblin MR, Ohadi E, Asadi A, Halajzadeh M, Lohrasbi V, Mohammadzadeh N, Amiriani T, Krutova M, Amini A, Kouhsari E (2019) Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities. Cancer Med 8(6):3167–3181. https://doi.org/10.1002/cam4.2148
Shindoh N, Mori M, Terada Y, Oda K, Amino N, Kita A, Taniguchi M, Sohda K-Y, Nagai K, Sowa Y, Masuoka Y, Orita M, Sasamata M, Matsushime H, Furuichi K, Sakai T (2008) YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model. Int J Oncol 32(3):545–555. https://doi.org/10.3892/ijo.32.3.545
Shin-ya K, Wierzba K, Matsuo K, Ohtani T, Yamada Y, Furihata K, Hayakawa Y, Seto H (2001) Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. J Am Chem Soc 123(6):1262–1263. https://doi.org/10.1021/ja005780q
Singh BP, Rateb ME, Rodriguez-Couto S et al (2019) Front Microbiol 10:914. https://doi.org/10.3389/fmicb.2019.00914
Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Man Lei Y, Jabri B, Alegre M-L, Chang EB, Gajewski TF (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science 350(6264):1084–1089. https://doi.org/10.1126/science.aac4255
St. Jean AT, Swofford CA, Panteli JT, Brentzel ZJ, Forbes NS (2014) Bacterial delivery of Staphylococcus aureus α-hemolysin causes regression and necrosis in murine tumors. Mol Ther 22(7):1266–1274. https://doi.org/10.1038/mt.2014.36
Suganya K, Govindan K, Prabha P, Murugan M (2017) An extensive review on L-methioninase and its potential applications. Biocatal Agric Biotechnol 12:104–115. https://doi.org/10.1016/j.bcab.2017.09.009
Sugumaran A, Pandiyan R, Kandasamy P, Antoniraj MG, Navabshan I, Sakthivel B, Dharmaraj S, Chinnaiyan SK, Ashokkumar V, Ngamcharussrivichai C (2022) Marine biome-derived secondary metabolites, a class of promising antineoplastic agents: a systematic review on their classification, mechanism of action and future perspectives. Sci Total Environ 836:155445. https://doi.org/10.1016/j.scitotenv.2022.155445
Sung WS, Park Y, Choi C-H, Hahm K-S, Lee DG (2007) Mode of antibacterial action of a signal peptide, pep 27 from Streptococcus pneumoniae. Biochem Biophys Res Commun 363(3):806–810. https://doi.org/10.1016/j.bbrc.2007.09.041
Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, Mac Donald S, Mao J, Sznol M, Rosenberg SA (2002) Phase I study of the intravenous administration of attenuated salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 20(1):142–152
Vaishnav P, Demain AL (2011) Unexpected applications of secondary metabolites. Biotechnol Adv 29(2):223–229. https://doi.org/10.1016/j.biotechadv.2010.11.006
Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CPM, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Zitvogel L (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350(6264):1079–1084. https://doi.org/10.1126/science.aad1329
Vijayvargia R, Suresh CG, Krishnasastry MV (2004) Functional form of Caveolin-1 is necessary for the assembly of α-hemolysin. Biochem Biophys Res Commun 324(3):1130–1136. https://doi.org/10.1016/j.bbrc.2004.09.164
Villarante KI, Elegado FB, Iwatani S, Zendo T, Sonomoto K, de Guzman EE (2011) Purification, characterization and in vitro cytotoxicity of the bacteriocin from Pediococcus acidilactici K2a2-3 against human colon adenocarcinoma (HT29) and human cervical carcinoma (HeLa) cells. World J Microbiol Biotechnol 27(4):975–980. https://doi.org/10.1007/s11274-010-0541-1
Wang Y, Guo W, Wu X, Zhang Y, Mannion C, Brouchkov A, Man Y-G, Chen T (2019) Oncolytic bacteria and their potential role in bacterium-mediated tumour therapy: a conceptual analysis. J Cancer 10(19):4442–4454. https://doi.org/10.7150/jca.35648
Wang D, Wei X, Kalvakolanu DV, Guo B, Zhang L (2021) Perspectives on oncolytic salmonella in cancer immunotherapy—A promising strategy. Front Immunol 12:615930. https://doi.org/10.3389/fimmu.2021.615930
Weerakkody LR, Witharana C (2019) The role of bacterial toxins and spores in cancer therapy. Life Sci 235:116839. https://doi.org/10.1016/j.lfs.2019.116839
Williams EM, Little RF, Mowday AM, Rich MH, Chan-Hyams JVE, Copp JN, Smaill JB, Patterson AV, Ackerley DF (2015) Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility. Biochem J 471(2):131–153. https://doi.org/10.1042/BJ20150650
Wolf P, Elsässer-Beile U (2009) Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. Int J Med Microbiol 299(3):161–176. https://doi.org/10.1016/j.ijmm.2008.08.003
Wu G (2013) Functional amino acids in nutrition and health. Amino Acids 45(3):407–411. https://doi.org/10.1007/s00726-013-1500-6
Xu G, McLeod HL (2001) Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res 7(11):3314–3324
Yaghoubi A, Khazaei M, Avan A, Hasanian SM, Cho WC, Soleimanpour S (2020) P 28 bacterial peptide, as an anticancer agent. Front Oncol 10:1303. https://doi.org/10.3389/fonc.2020.01303
Yang J, Tao R, Wang L, Song L, Wang Y, Gong C, Yao S, Wu Q (2019) Thermosensitive micelles encapsulating phenylalanine ammonia lyase act as a sustained and efficacious therapy against colorectal cancer. J Biomed Nanotechnol 15(4):717–727. https://doi.org/10.1166/jbn.2019.2734
Yu F-L, Liu T-T, Zhu X, Yang W-X, Zhang T, Lin N, Liu Y, Liu C-S, Jiang J, Guan J-C (2013) Staphylococcal enterotoxin B and α-toxin induce the apoptosis of ECV304 cells via similar mechanisms. Mol Med Rep 8(2):591–596. https://doi.org/10.3892/mmr.2013.1550
Zhang HL, Hua HM, Pei YH, Yao XS (2004) Three new cytotoxic cyclic acylpeptides from marine bacillus sp. Chem Pharm Bull 52(8):1029–1030. https://doi.org/10.1248/cpb.52.1029
Zhang L, Liu M, Jamil S, Han R, Xu G, Ni Y (2015) PEGylation and pharmacological characterization of a potential anti-tumor drug, an engineered arginine deiminase originated from pseudomonas plecoglossicida. Cancer Lett 357(1):346–354. https://doi.org/10.1016/j.canlet.2014.11.042
Zhang Y, Schulte W, Pink D, Phipps K, Zijlstra A, Lewis JD, Waisman DM (2010) Sensitivity of cancer cells to truncated diphtheria toxin. PLoS One 5(5):e10498. https://doi.org/10.1371/journal.pone.0010498
Zhang J-N, Xia Y-X, Zhang H-J (2021) Natural cyclopeptides as anticancer agents in the last 20 years. Int J Mol Sci 22(8):3973. https://doi.org/10.3390/ijms22083973
Zhou S, Gravekamp C, Bermudes D, Liu K (2018) Tumour-targeting bacteria engineered to fight cancer. Nat Rev Cancer 18(12):Article 12. https://doi.org/10.1038/s41568-018-0070-z
Zhu L, Tee KL, Roccatano D, Sonmez B, Ni Y, Sun Z-H, Schwaneberg U (2010) Directed evolution of an antitumor drug (arginine deiminase PpADI) for increased activity at physiological pH. ChemBioChem 11(5):691–697. https://doi.org/10.1002/cbic.200900717
Zhu L, Verma R, Roccatano D, Ni Y, Sun Z-H, Schwaneberg U (2010) A potential antitumor drug (arginine deiminase) reengineered for efficient operation under physiological conditions. ChemBioChem 11(16):2294–2301. https://doi.org/10.1002/cbic.201000458
Zu C, Wang J (2014) Tumor-colonizing bacteria: a potential tumor targeting therapy. Crit Rev Microbiol 40(3):225–235. https://doi.org/10.3109/1040841X.2013.776511
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Jangra, N., Kawatra, A., Dhankhar, R., Gulati, P. (2023). Bacteria and Bacteria-Based Products in Cancer Therapy: Current Status and Future Advances. In: Sobti, R., Kuhad, R.C., Lal, R., Rishi, P. (eds) Role of Microbes in Sustainable Development. Springer, Singapore. https://doi.org/10.1007/978-981-99-3126-2_20
Download citation
DOI: https://doi.org/10.1007/978-981-99-3126-2_20
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-3125-5
Online ISBN: 978-981-99-3126-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)